Kevin Song

Sep 9, 2024 | digitalcommons.library.tmc.edu | Yue Hu |Abhijit Sarkar |Kevin Song |Sara Michael

AbstractChimeric antigen receptor (CAR) T cell therapy is hindered in solid tumor treatment due to the immunosuppressive tumor microenvironment and suboptimal T cell persistence. Current strategies do not address nutrient competition in the microenvironment. Hence, we present a metabolic refueling approach using inosine as an alternative fuel. CAR T cells were engineered to express membrane-bound CD26 and cytoplasmic adenosine deaminase 1 (ADA1), converting adenosine to inosine.

Apr 29, 2024 | cell.com | Yue Hu |Inflammatory Diseases |Abhijit Sarkar |Kevin Song

Highlights•ADA1 is conditionally secreted in response to CD3/CD26 stimulation•Co-overexpression of ADA1 and CD26 is essential for T cell trafficking and expansion•Ecto-ADA1 boosts CAR T cell expansion without impacting tumor cells•MR-CAR is a strategy to improve CAR T cell therapy for solid tumorsSummaryChimeric antigen receptor (CAR) T cell therapy is hindered in solid tumor treatment due to the immunosuppressive tumor microenvironment and suboptimal T cell persistence.

Sep 22, 2023 | biorxiv.org | Yue Hu |Abhijit Sarkar |Kevin Song |Sara Michael

AbstractCAR T cell therapy has revolutionized the treatment of hematologic malignancies, but its efficacy in solid tumors remains limited due to the immunosuppressive nature of the tumor microenvironment and the inability of T cells to persist and traffic to the tumor site.